

*Appl. Serial No. 10/590,435*  
*Response October 14, 2010*

- 2 -

**Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection consisting of [comprising a]-peptide [consisting of] ANX (SEQ. ID. NO. 28), wherein X is any amino acid except cysteine, [or an isomer thereof, a retro or a retro-inverso isomer thereof,] or a salt thereof.
2. (Previously Amended) The antifibrillogenic agent of claim 1, wherein X is I or F.
3. (Currently Amended) The antifibrillogenic agent of claim 1, wherein the [agent comprises a] peptide is [consisting of] ANF (SEQ. ID. NO. 24), [or an isomer thereof, a retro or a retro-inverso isomer thereof,] or a salt thereof.
4. (Previously Canceled)
5. (Previously Canceled)
6. (Previously Canceled)
7. (Previously Canceled)
8. (Previously Canceled)
9. (Currently Amended) The antifibrillogenic agent of claim 1, wherein said peptide is ANX (SEQ. ID. NO. 28) wherein X is any amino acid except cysteine, or a salt thereof.
10. (Previously Amended) The antifibrillogenic agent of claim 9, wherein X is I or F.
11. (Currently Amended) The antifibrillogenic agent of claim 10, wherein the peptide is ANF (SEQ. ID. NO. 24), or a salt thereof.
12. (Canceled)
13. (Previously presented) The antifibrillogenic agent of claim 1, wherein said amyloidosis is IAPP-related.
14. (Previously Amended) The antifibrillogenic agent of claim 1, wherein said amyloidosis is type 1 or type 2 diabetes.

*Appln. Serial No. 10/590,435*  
*Response October 14, 2010*

- 3 -

15. (Previously Amended) A composition for inhibiting amyloidosis and/or for cytoprotection, comprising a therapeutically-effective amount of the antifibrillogenic agent of claim 1 in association with a pharmaceutically-acceptable carrier.
16. (Previously Amended) A composition for inhibiting amyloidosis and/or for cytoprotection, comprising a therapeutically-effective amount of the antifibrillogenic agent of claim 9 in association with a pharmaceutically-acceptable carrier.
17. (Previously Canceled)
18. (Previously Canceled)
19. (Previously Canceled)
20. (Previously Canceled)
21. (Previously Canceled)
22. (Previously Canceled)
23. (Previously Canceled)
24. (Previously Canceled)
25. (Previously Canceled)
26. (Previously Canceled)
27. (Previously Canceled)
28. (Previously Canceled)
29. (Previously Canceled)
30. (Previously Canceled)
31. (Previously Canceled)
32. (Canceled)
33. (Canceled)
34. (Canceled)
35. (Previously Canceled)
36. (Previously Canceled)
37. (Previously Canceled)
38. (Previously Canceled)
39. (Canceled)
40. (Canceled)

DOCS #9725793 v. 1

*Appln. Serial No. 10/590,435*  
*Response October 14, 2010*

- 4 -

41. (Canceled)
42. (Canceled)
43. (Canceled)
44. (Canceled)
45. (Canceled)
46. (Canceled)
47. (Canceled)
48. (Canceled)
49. (Canceled)
50. (Previously Canceled)
51. (Previously Canceled)
52. (Previously Canceled)
53. (Previously Canceled)
54. (Previously Canceled)
55. (Previously Canceled)
56. (Canceled)
57. (Canceled)
58. (Canceled)
59. (Canceled)
60. (Canceled)
61. (Canceled)
62. (Currently Amended) A composition for inhibiting amyloidosis and/or for cytoprotection, comprising a therapeutically-effective amount of the antifibrillogenic agent of claim 10 or[ro] a salt thereof in association with a pharmaceutically-acceptable carrier.
63. (Previously Presented) A composition for inhibiting amyloidosis and/or for cytoprotection, comprising a therapeutically-effective amount of the antifibrillogenic agent of claim 11 or a salt thereof in association with a pharmaceutically-acceptable carrier.
64. (New) A composition for inhibiting amyloidosis and/or for cytoprotection, comprising a therapeutically-effective amount of the antifibrillogenic agent of claim 3 in association with a pharmaceutically-acceptable carrier.